Brevan Howard Capital Management LP Raises Stock Holdings in Eli Lilly and Company $LLY

Brevan Howard Capital Management LP boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1,283.8% in the second quarter, HoldingsChannel.com reports. The fund owned 20,176 shares of the company’s stock after acquiring an additional 18,718 shares during the quarter. Brevan Howard Capital Management LP’s holdings in Eli Lilly and Company were worth $15,728,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Wellington Management Group LLP raised its position in Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after buying an additional 81,587 shares during the last quarter. Laurel Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $8,827,714,000. Finally, Jennison Associates LLC increased its stake in shares of Eli Lilly and Company by 4.3% in the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after acquiring an additional 226,620 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent research reports. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Wednesday. HSBC reaffirmed a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. BMO Capital Markets set a $1,200.00 target price on Eli Lilly and Company in a report on Thursday, December 4th. Finally, Daiwa Capital Markets lifted their price target on Eli Lilly and Company from $700.00 to $940.00 in a research report on Monday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,109.24.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,027.68 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The stock’s 50-day moving average price is $939.47 and its 200-day moving average price is $818.98. The stock has a market capitalization of $971.55 billion, a PE ratio of 50.28, a price-to-earnings-growth ratio of 1.12 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.